Century Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M | — |
| Research and development | $95.7M | $107.2M | $92.7M | $97.2M | $75.6M |
| Operating expenses | $126.4M | $144.7M | $148.8M | $139.0M | $94.9M |
| Operating income | -$17.3M | -$138.1M | -$146.5M | -$133.8M | -$94.9M |
| Interest expense | — | — | $540,000 | $1.0M | $1.3M |
| Pretax income | -$9.6M | -$124.8M | -$134.8M | -$130.8M | -$95.8M |
| Income tax expense | -$68,000 | $1.8M | $1.9M | $91,000 | $43,000 |
| Net income | -$9.6M | -$126.6M | -$136.7M | -$130.9M | -$95.8M |
| Balance Sheet | |||||
| Cash and equivalents | $61.9M | $58.4M | $47.3M | $84.3M | $56.4M |
| Current assets | $120.8M | $194.1M | $177.0M | $319.7M | $228.2M |
| Total assets | $223.7M | $353.2M | $360.7M | $486.5M | $437.4M |
| Current liabilities | $20.2M | $129.8M | $17.8M | $29.8M | $15.7M |
| Total liabilities | $64.8M | $191.9M | $175.9M | $183.8M | $41.1M |
| Total debt | — | — | — | $10.0M | $10.0M |
| Stockholders' equity | $158.9M | $161.4M | $184.8M | $302.7M | $396.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$103.9M | -$110.1M | -$88.3M | $14.1M | -$89.0M |
| Depreciation and amortization | $13.1M | $13.3M | $13.0M | $8.4M | $3.7M |
| Stock-based compensation | $6.8M | $12.7M | $14.6M | $10.7M | $4.7M |
| Capital expenditure | $848,000 | $154,000 | $13.7M | $30.6M | $45.0M |
| Free cash flow | -$104.7M | -$110.3M | -$102.1M | -$16.6M | -$134.0M |
| Impairments | $6.8M | $4.3M | $16.4M | — | — |
Shares outstanding 180.4M · Free float 85.3%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.